Clinical trial · Observational
Circulating Tumor Cells for Hepatocellular Carcinoma
Circulating Tumor Cells (CTCs) as Biomarkers of Prognosis and Predictors of Efficacy of Drug Therapy for Patients With Hepatocellular Carcinoma
NCT01930383CI-TRIAL-00012638CTCs for HCCunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the clinical value of circulating tumor cells (CTCs) measurement for Hepatocellular carcinoma (HCC) patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Neoplasm Circulating Cells | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- Arm A
- description
- HCC patients who receive curative surgery or radiofrequency ablation therapy
- label
- Arm B
- description
- patients who receive trans-arterial chemoembolization
- label
- Arm C
- description
- patients who receive systemic therapy
Primary outcomes (1)
- measure
- Numbers of circulating tumor cells
- timeFrame
- in 24 months
- description
- CTCs are measured by microfluidic disk platform. They are defined as tumor cells that are circulating in the peripheral blood of patients, which are shed from either the primary tumor or its metastases.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patient must be diagnosed with HCC via one of following methods according to present clinical practice: 1. Diagnosed as HCC by biopsy or cytology 2. Patients with chronic hepatitis B or other reason induced liver cirrhosis who have diagnosed as HCC based on a typical contrast enhanced CT or MRI profile with malignant lesion \[tumor hyper-vascularization\]. * Asian male or female subjects \>=20 years of age. * Child-Pugh class A or B liver function.. * HCC patients who will receive anti-cancer therapy, including surgery, radiofrequency ablation therapy, trans-arterial chemoembolization, or systemic therapy (according to current HCC practice guidelines) at National Taiwan University Hospital. * Signed informed consent. Exclusion Criteria: * Other significant organ disease or condition his/her investigator judged that the subject should not participate in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.